Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2022-04-15 Report Publication Anno…
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Modalités de mise à disposition de document de référence ou de ses actualisations
Report Publication Announcement Classification · 98% confidence The document is titled "Mise à disposition du document d'enregistrement universel" (Making available of the universal registration document). It explicitly states that the company has made available and filed its 'document d'enregistrement universel' (Universal Registration Document - URD) for the year 2020 with the AMF (Autorité des marchés financiers) on April 14th. The URD contains the annual financial report for 2020, semi-annual accounts for June 30, 2021, and governance reports. Since the document itself is an announcement about the availability of a major regulatory filing (the URD, which often incorporates elements of the 10-K/AR/MDA), and given its short length (4671 chars) and focus on *making available* the report rather than presenting the full content, it fits the definition of a Report Publication Announcement (RPA). The URD is a comprehensive filing, but this specific text is the announcement of its publication.
2022-04-15 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 99% confidence The document is a press release from Genomic Vision announcing the establishment of a new financing line of up to 30 M€ with Winance. It details the terms, including the issuance of convertible bonds with warrants (OCABSA), the need for shareholder approval via an Extraordinary General Meeting (AGE), and the planned use of funds. This clearly falls under the category of updates on company fundraising and capital structure changes. Keywords supporting this classification include: 'nouvelle ligne de financement', 'financement', 'OCABSA' (Obligations Convertibles en Actions avec Bons de Souscription d'Actions), 'assemblée générale extraordinaire', and 'besoins d'investissements et de financement de la croissance'. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K), but a specific announcement about securing capital.
2022-04-11 French
Inside Information / Other news releases
Capital/Financing Update Classification · 98% confidence The document is an announcement by Genomic Vision regarding the implementation of a new financing line of up to €30 million with Winance. The core subject is the provision of capital, subject to shareholder approval (EGM). This directly relates to fundraising, financing activities, and changes in capital structure. According to the definitions, this aligns perfectly with the 'Capital/Financing Update' category (CAP). Although it mentions an Extraordinary General Meeting (EGM) for approval, the primary purpose of the release is the financing deal itself, not the voting results (DVA) or the AGM materials (AGM-R). It is not a full financial report (10-K or IR) or an earnings release (ER).
2022-04-11 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release from Genomic Vision announcing that the University of Florida has adopted its technology for DNA replication studies. It details the technology, quotes researchers and the company's CEO, and includes standard 'About Us' and 'Contact' sections, concluding with a forward-looking statement disclaimer. This format is characteristic of a general corporate announcement or news release, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is an announcement about the company's business activities and partnerships, and it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), the most appropriate classification is the general regulatory announcement/news category, which is RNS (Regulatory Filings), as it serves as a general disclosure to the market about a significant business development. The document length is substantial (7136 chars), so it is not a simple RPA.
2022-02-17 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Genomic Vision's technology has been acquired by the University of South Florida for research purposes, funded by the NIH. It details the technology, quotes professors and the CEO, and includes standard boilerplate sections like 'ABOUT GENOMIC VISION', 'CONTACTS', and 'FORWARD LOOKING STATEMENT'. This type of announcement, which is not a formal regulatory filing (like 10-K, IR, or ER) but rather a business development update, fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'LTR' if it were about a legal matter, but here it is a positive business development. Given the options, RNS serves as the best general category for non-standard, yet important, corporate news releases that don't fit the specific financial report codes. It is not an Earnings Release (ER), Interim Report (IR), or a specific filing like DEF 14A or 10-K. It is a general announcement.
2022-02-17 English
Inside Information / Other news releases
Earnings Release Classification · 98% confidence The document provides a summary of financial performance, specifically reporting revenue and cash position for the Fourth Quarter and Full Year 2021, ending December 31, 2021. It includes key figures, tables comparing performance year-over-year, and a section on the financial structure/cash runway. It also announces the next communication date for the Full Year results (April 21, 2022). This structure—a concise release highlighting key period results without being the full, audited annual report (10-K) or a comprehensive interim report (IR)—is characteristic of an Earnings Release (ER). It is not a transcript (CT), a proxy statement (PSI), or a formal annual report (10-K). The document is a press release announcing the results. Q4 2021
2022-02-15 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.